479. Long Term Follow Up of Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpes Virus (Talimogene Laherparepvec, T-Vec) in Patients With Unresectable Metastatic Melanoma
Molecular Therapy - United States
doi 10.1016/s1525-0016(16)34814-6
